Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ACERUS PHARMACEUTICALS CORP (OTC: TRLPF).

Full DD Report for TRLPF

You must become a subscriber to view this report.


Recent News from (OTC: TRLPF)

Acerus Pharmaceuticals' (TRLPF) CEO Edward Gudaitis on Q1 2018 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corp. (TRLPF) Q1 2018 Earnings Conference Call May 15, 2018, 08:30 AM ET Executives Edward Gudaitis - President & CEO Ken Yoon - CFO Nathan Bryson - VP, Scientific Affairs Tricia Symmes - Chief Operating Officer Philippe Savard - VP & General C...
Source: SeekingAlpha
Date: May, 15 2018 12:12
Acerus Pharmaceuticals' (TRLPF) CEO Luc Mainville on Q4 2017 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corporation (TRLPF) Q4 2017 Results Earnings Conference Call March 21, 2018, 8:30 am ET Executives Luc Mainville - Interim Chief Executive Officer Ken Yoon - Chief Financial Officer Nathan Bryson - Vice President, Scientific Affairs Analysts Andre Udd...
Source: SeekingAlpha
Date: March, 21 2018 11:33
Innovus Pharma inks deal with Acerus Pharma to commercialize Urivarx in Canada
Innovus Pharmaceuticals ( OTCQB:INNV ) has entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals ( OTCPK:TRLPF ) for its product UriVarx in Canada. More news on: Innovus Pharmaceuticals, Inc., ACERUS PHARMACEUTICALS CORP, Healthcare stocks news, Rea...
Source: SeekingAlpha
Date: January, 08 2018 06:35
Acerus Pharmaceuticals' (TRLPF) CEO Luc Mainville on Q3 2017 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corporation (TRLPF) Q3 2017 Earnings Conference Call November 07, 2017 8:30 AM ET Executives Luc Mainville - Interim President and Chief Executive Officer Ken Yoon - Chief Financial Officer Nathan Bryson - Vice President, Scientific Affairs Philippe Savar...
Source: SeekingAlpha
Date: November, 07 2017 14:01
Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2017 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corporation (TRLPF) Q2 2017 Earnings Conference Call August 11, 2017 8:30 a.m. ET Executives Tom Rossi - CEO Ken Yoon - CFO Analysts Scott Henry - ROTH Capital Partners Presentation Operator Good morning, ladies and gentlemen, and welcome to t...
Source: SeekingAlpha
Date: August, 11 2017 14:47
Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q1 2017 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corp. (TRLPF) Q1 2017 Earnings Conference Call May 16, 2017, 8:30 am ET Executives Tom Rossi - President & CEO Analysts Scott Henry - ROTH Capital Presentation Operator All participants please standby, your conference is ready to begin. Good...
Source: SeekingAlpha
Date: May, 15 2017 10:06
Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q4 2016 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corp. (TRLPF) Q4 2016 Earnings Conference Call March 8, 2017, 8:30 am ET Executives Tom Rossi - President & CEO Analysts Presentation Operator All participants please standby, your conference is ready to begin. Good morning, ladies and gentlem...
Source: SeekingAlpha
Date: March, 08 2017 10:00
Acerus Pharmaceuticals reports Q4 results
Acerus Pharmaceuticals ( OTCPK:TRLPF ): Q4 EPS of $0.00 Revenue of $1.8M (-77.8% Y/Y) Press Release More news on: ACERUS PHARMACEUTICALS CORP, Earnings news and commentary, ,
Source: SeekingAlpha
Date: March, 08 2017 07:19
Acerus Pharmaceuticals reports Q3 results
Acerus Pharmaceuticals ( OTCPK:TRLPF ): Q3 EPS of $0.00 More news on: ACERUS PHARMACEUTICALS CORP, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: November, 02 2016 07:09
Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call Transcript
Acerus Pharmaceuticals Corp (TRLPF) Q2 2016 Earnings Conference Call August 9, 2016 8:30 AM ET Executives Tom Rossi - President and Chief Executive Officer Analysts Joseph Walewicz - LBS Presentation Operator Good morning, ladies and gentlemen. Welcome to the Second Q...
Source: SeekingAlpha
Date: August, 09 2016 12:28

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.2020.2020.2020.20210,000
2018-08-20N/A0.154N/AN/A0
2018-08-17N/A0.154N/AN/A0
2018-08-16N/A0.154N/AN/A0
2018-08-150.1540.1540.1540.154124

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-132,50017,95313.9252Cover
2018-07-273007,8003.8462Cover
2018-07-24237237100.0000Short
2018-07-205,0015,001100.0000Short
2018-07-02999999100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TRLPF.


About ACERUS PHARMACEUTICALS CORP (OTC: TRLPF)

Logo for ACERUS PHARMACEUTICALS CORP (OTC: TRLPF)

Not available

 

Contact Information

 

 

Current Management

  • Tom Rossi / CEO, President
  • Kenneth Howling / CFO

Current Share Structure

  • Market Cap: $39,993,861 - 03/09/2018
  • Issue and Outstanding: 200,873,234 - 09/01/2014

 



Daily Technical Chart for (OTC: TRLPF)

Daily Technical Chart for (OTC: TRLPF)


Stay tuned for daily updates and more on (OTC: TRLPF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TRLPF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TRLPF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TRLPF and does not buy, sell, or trade any shares of TRLPF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/